Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction.
adherence
adverse drug reactions
drug safety
nuclear magnetic resonance
translational research
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
09
2020
accepted:
04
11
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Type V-phosphodiesterase-inhibitors (PDE5i) are the first choice drugs in the treatment of erectile dysfunction (ED), being effective in 60-70% of patients. However, approximately 50% of patients per year discontinue the treatment with PDE5i after reporting poor drug efficacy or major adverse drug reactions (ADR). To identify early markers of efficacy/safety for the treatment of ED with PDE5i, the basal clinical characteristics of patients, integrated with metabolomics analysis of serum and urine and genomic data, were here correlated with the PDE5i efficacy and the occurrence of ADR upon administration. Thirty-six males with new diagnosis of ED were consecutively recruited and characterized at baseline for anthropometrics, blood pressure, blood glucose, lipid profile, serum levels of thyroid/sex hormones and erectile function evaluated by IIEF-15 questionnaire. Targeted Next Generation Sequencing (NGS) was applied to genes involved in PDE5i pharmacodynamics and pharmacokinetics. Fasting metabolic profiles of serum and urine were assessed by nuclear magnetic resonance (NMR)-based metabolomics analysis. Patients were prescribed on-demand therapy with Sildenafil oro-dispersible film and followed-up after 3 months from recruitment. Baseline data were compared with IIEF-15 score at follow-up and with the occurrence of ADR recorded by a dedicated questionnaire. Twenty-eight patients were finally included in the analysis. Serum LDL-cholesterol levels were increased in those reporting ADR (143.3 ± 13.2 mg/dl ADR vs. 133.1 ± 12.4 mg/dl No ADR;
Identifiants
pubmed: 33536912
doi: 10.3389/fphar.2020.602369
pii: 602369
pmc: PMC7849189
doi:
Types de publication
Journal Article
Langues
eng
Pagination
602369Informations de copyright
Copyright © 2020 Rocca, Vignoli, Tenori, Ghezzi, De Rocco Ponce, Vatsellas, Thanos, Padrini, Foresta and De Toni.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S
pubmed: 11879256
BJU Int. 2009 May;103(10):1392-5
pubmed: 19154494
J Clin Pharmacol. 1999 Aug;39(8):826-33
pubmed: 10434235
Andrology. 2016 Nov;4(6):1002-1009
pubmed: 27636710
Brief Bioinform. 2013 May;14(3):315-26
pubmed: 22786785
Angew Chem Int Ed Engl. 2019 Jan 21;58(4):968-994
pubmed: 29999221
Front Pharmacol. 2018 Feb 06;9:59
pubmed: 29467656
Clin Pharmacol Drug Dev. 2015 Jan;4(1):74-80
pubmed: 27128005
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Manag Care Interface. 2006 Nov;19(11):22-6, 36
pubmed: 17137237
Br J Clin Pharmacol. 2019 Aug;85(8):1684-1691
pubmed: 30933373
Int J Impot Res. 2010 Jan-Feb;22(1):51-60
pubmed: 19865092
Patient Prefer Adherence. 2018 Jul 13;12:1225-1230
pubmed: 30034226
Clin Cornerstone. 2005;7(1):57-65
pubmed: 16156424
Nat Rev Dis Primers. 2016 Feb 04;2:16003
pubmed: 27188339
J Bone Miner Res. 2018 Dec;33(12):BM i-BM ii
pubmed: 30521121
Andrology. 2019 Jan;7(1):82-87
pubmed: 30407754
Am J Hypertens. 2006 Sep;19(9):915-9
pubmed: 16942933
Mayo Clin Proc. 2012 Aug;87(8):766-78
pubmed: 22862865
Pharmacogenomics. 2014 Aug;15(11):1519-38
pubmed: 25303302
Front Pharmacol. 2020 May 07;11:555
pubmed: 32457604
J Sex Med. 2010 May;7(5):1937-47
pubmed: 20202105
N Engl J Med. 1998 May 14;338(20):1397-404
pubmed: 9580646
BMC Health Serv Res. 2007 Apr 17;7:55
pubmed: 17439645
Drug Metab Dispos. 2019 Oct;47(10):1066-1079
pubmed: 31399507
BMC Med. 2019 Jan 7;17(1):3
pubmed: 30616610
Int J Impot Res. 2004 Jun;16 Suppl 1:S11-4
pubmed: 15224129
Anal Chem. 2018 Oct 16;90(20):11962-11971
pubmed: 30211542
J Sex Med. 2019 Mar;16(3):394-401
pubmed: 30773501
Clin Pharmacol Ther. 2015 Dec;98(6):602-10
pubmed: 26352006
Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011
pubmed: 25412402
J Sex Med. 2011 Dec;8(12):3418-32
pubmed: 21995676
Am J Cardiol. 1999 Mar 4;83(5A):3C-12C
pubmed: 10078537
J Sex Med. 2005 Nov;2(6):848-55
pubmed: 16422809
BMC Genomics. 2013 Nov 18;14:798
pubmed: 24246134
N Engl J Med. 2005 Aug 4;353(5):487-97
pubmed: 16079372